177lu-lnc1004
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 3, 2023 (NCT05723640)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06898437 | Early Phase 1 (Phase 1) | Mar 24, 2025 | Chinese Academy of Medical Sciences |
| NCT05723640 | Phase 1 | Oct 3, 2023 | Yantai LNC Biotechnology Singapore PTE. LTD. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Yantai LNC Biotechnology Singapore PTE. LTD. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1